Direkt zum Inhalt
Merck

11086090001

Roche

Calpain-Inhibitor I

N-Acetyl-Leu-Leu-norleucinal, synthetic

Synonym(e):

Kalpain-Inhibitor I, ALLN, Ac-LLnL-CHO, MG-101, N-Acetyl-L-leucyl-L-leucyl-L-norleucinal, N-Acetyl-Leu-Leu-Norleu-al

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C20H37N3O4
CAS-Nummer:
Molekulargewicht:
383.53
Beilstein:
7656053
MDL-Nummer:
UNSPSC-Code:
12352204
PubChem Substanz-ID:

Qualitätsniveau

Assay

98% (chromatographically homogeneous)

Form

powder

Mol-Gew.

Mr = 383.5

Verpackung

pkg of 25 mg

Hersteller/Markenname

Roche

mp (Schmelzpunkt)

182 °C

Löslichkeit

DMF: 10 mg/mL
ethanol: 10 mg/mL
methanol: 10 mg/mL

Lagertemp.

2-8°C

SMILES String

[H]C(=O)[C@H](CCCC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O

InChI

1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1

InChIKey

FMYKJLXRRQTBOR-BZSNNMDCSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Calpain Inhibitor I is a strong, competitive inhibitor of the Ca2+-dependent neutral cysteine proteases calpain I and calpain II.

Spezifität

Calpain Inhibitor I is a strong, competitive inhibitor of the Ca2+-dependent neutral cysteine proteases calpain I (requiring 2–75 μM Ca2+ for activation) and calpain II (requiring 200–800 μM) with a Ki-value between 0.12 μM and 0.23 μM. Calpain II is inhibited to a lesser extent than calpain I. Calpain Inhibitor I is also a strong inhibitor of papain and cathepsin B and L. It shows only weak inhibition of cathepsin H and α-chymotrypsin and does not inhibit trypsin. ID50 for 0.02 U platelet calpain is 0.05 μM.

Anwendung

Calpain inhibitor I inhibits calpain, which activates myosin light chain kinase and protein kinase C by partial proteolysis. The inhibitor should be membrane permeable due to low molecular weight and lack of charged residues.
Calpain Inhibitor I is used for western blotting methods.

Qualität

Purity: 98% (from C); chromatographically homogeneous

Alternative Formulierung

C20H37N3O4

Angaben zur Herstellung

Working concentration: 0.1 - 10 μM
The suggested starting concentration is 17 μg/ml. This is the concentration at which half maximal inhibition of calpain I is observed.
Working solution: Recommended solvent is DMF, ethanol, or methanol up to 10 mg/ml.
Storage conditions (working solution): -15 to -25 °C
Solutions in DMF, methanol, ethanol are stable for 4 weeks at -15 to -25 °C.

Rekonstituierung

Soluble in DMF, ethanol, or methanol to 10 mg/ml. For a stock solution, Roche recommends dissolving 1 mg of the inhibitor in 100 μl DMF, methanol, or ethanol. Before use, dilute with water or phosphate buffer (0.1 M, pH 7.5) to desired concentration. Solutions in DMF, ethanol, or methanol are stable for 2 to 3 days at 2 to 8 °C, and approximately 4 weeks at -15 to -25 °C. For best results, prepare solutions fresh before use.

Sonstige Hinweise

For life science research only. Not for use in diagnostic procedures.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Erdinç Dursun et al.
Journal of Alzheimer's disease : JAD, 23(2), 207-219 (2010-10-23)
Amyloid-β (Aβ) is the core component of amyloid plaques of Alzheimer's disease (AD). The effects of Aβ include damage to neuronal plasma membrane, disruption of Ca(2+) homeostasis, and alterations of neurotrophic factor levels. The aim of this study was to
Takahisa Hirokawa et al.
International journal of molecular sciences, 22(15) (2021-08-08)
Tauopathies are neurodegenerative diseases characterized by abnormal metabolism of misfolded tau proteins and are progressive. Pathological phosphorylation of tau occurs in the retinal ganglion cells (RGCs) after optic nerve injuries. Cyclin-dependent kinase-5 (Cdk5) causes hyperphosphorylation of tau. To determine the
Sami Salmikangas et al.
Microorganisms, 8(12) (2020-12-10)
The current methods to study the distribution and dynamics of viral RNA molecules inside infected cells are not ideal, as electron microscopy and immunohistochemistry can only detect mature virions, and quantitative real-time PCR does not reveal localized distribution of RNAs.
Duygu Gezen-Ak et al.
PloS one, 6(3), e17553-e17553 (2011-03-17)
Recent studies have suggested that vitamin D can act on cells in the nervous system. Associations between polymorphisms in the vitamin D receptor (VDR), age-dependent cognitive decline, and insufficient serum 25 hydroxyvitamin D(3) levels in Alzheimer's patients and elderly people

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.